Division of Teva Pharmaceutical Industries Ltd.
Latest From Actavis Laboratories
A topical foam formulation of the antibiotic, minocycline, is expected to be a novel entrant into the US severe acne market. After positive top-line results from a confirmatory Phase III study, Foamix is stepping-up its financing and marketing plans.
A steady stream of M&A and licensing activity, starting with the buyout of Andrx in 2006, spurred Actavis’ a.k.a. Watson’s transformation into a global specialty pharma. This led the way to the 2012 merger with Actavis and now the proposed buyout of Forest, creating a new, global specialty and generics player.
Having decided that generics must reference reformulated OxyContin, the agency must determine the evidence needed for generics to show they provide equivalent abuse-deterrence.
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Andrx Corp.
- North America
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
Nicholas F Cappuccino, PhD, EVP, CSO
Jeffrey Long-McGie, VP, Bus. Dev.
- Contact Info
Phone: (954) 382-7600
8151 Peters Rd.
Davie, FL 33314
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.